FDA Approves Expanded Indication for Cerliponase Alfa to Treat CLN2 Disease in Children Under 3 Years

Published Date: 28 Jul 2024

The expanded indication, supported by a phase 2 open-label trial, includes children of all ages with CLN2 disease, regardless of whether they are symptomatic or asymptomatic.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot